MAI-001 by Nanjing Minova Pharmaceutical Technology for Depression: Likelihood of Approval

MAI-001 is under clinical development by Nanjing Minova Pharmaceutical Technology and currently in Phase I for Depression.

AbbVie purchases neuroscience developer Cerevel for $8.7 billion

Abbvie announced Wednesday that it will purchase Cerevel Therapeutics and its pipeline of experimental neurological and psychiatric medications for $8.7 billion. The deal marks the

December 6, 2023

Newborn Screening Metabolic Markers May Predict SIDS

Atypical metabolic markers from routine newborn screening were associated with sudden infant death syndrome (SIDS), a case-control study suggested. Fourteen metabolic markers significantly correlated with

September 10, 2024

What the Dana-Farber, Brigham divorce means for patients

When Sarah, a mother of two, was diagnosed with breast cancer in 2021 at the age of 43, she carefully considered where to go for

September 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.